Latest Pharma Insights
Incyte’s Transition From A Jakafi Company To A More Diversified Pharma
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Scrip - February 4, 2026
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Scrip - February 4, 2026
US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Lower US Tariffs Open Export Window For Indian Devices As Manufacturing Looks Away From China
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
More Accuracy Issues For Magellan Diagnostics Blood Lead Tests
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
Stryker Taps ASCs With Mako RPS As Mako 4 Drives Record Robot Installations
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Novo Takes Gloomy Approach To Cut Weight Of Expectations
New CEO Mike Doustdar believes Novo Nordisk can win in the lower-price, higher-volume consumer market for obesity drugs – but is nonetheless preparing investors for a hit to sales and profits in 2026.
Scrip - February 4, 2026
New CEO Mike Doustdar believes Novo Nordisk can win in the lower-price, higher-volume consumer market for obesity drugs – but is nonetheless preparing investors for a hit to sales and profits in 2026.
Scrip - February 4, 2026
Clarity For Certain Botanicals With EU Novel Food Updates
The latest round of updates to the European Commission's Novel Food Catalogue determine whether authorization is required for supplements containing certain botanical extracts.
HBW Insight - February 4, 2026
The latest round of updates to the European Commission's Novel Food Catalogue determine whether authorization is required for supplements containing certain botanical extracts.
HBW Insight - February 4, 2026
Novartis Gets Two New Blockbusters In Scemblix And Leqvio
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Scrip - February 4, 2026
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Scrip - February 4, 2026
Medtronic To Acquire Cathworks For $585M, Expanding Its Cardiology Portfolio
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
GSK Bets On New Launches And R&D Acceleration As Sales Headwinds Remain
CEO Luke Miels backs GSK’s 2031 sales target of £40bn despite incoming headwinds in vaccines and HIV.
Scrip - February 4, 2026
CEO Luke Miels backs GSK’s 2031 sales target of £40bn despite incoming headwinds in vaccines and HIV.
Scrip - February 4, 2026
Santhera’s DMD Research Is A Labor Of Love
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
Bausch And Lannett To Pay Up Nearly $18m In A US Price-Fixing Settlement
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
Sun On ‘Disciplined’ M&A Approach, Day-One Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
‘These Decisions Created A Lot Of Uncertainty’ – Why The Supreme Court’s Skinny-Label Ruling Matters
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
Novo Warns Of Steep Sales Decline In 2026, Blames US Price Cuts
The Danish firm’s share price plummeted as it revealed its most favored nation pricing deal would cut deep into sales and profits in 2026, although offset somewhat by strong launch of the Wegovy pill.
Scrip - February 4, 2026
The Danish firm’s share price plummeted as it revealed its most favored nation pricing deal would cut deep into sales and profits in 2026, although offset somewhat by strong launch of the Wegovy pill.
Scrip - February 4, 2026
Medtech Companies Seek More Device Input Into EU’s Cardiovascular Disease Plan
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Financing Quarterly Statistics, Q4 2025
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026
FDA CRL for Aquestive’s Anaphylm Comes With Clearer Path Forward
The FDA’s complete response letter for Aquestive Therapeutics’ allergy drug Anaphylm was limited to human factors validation and a single supportive pharmacokinetics study, defining a narrower path toward resubmission without additional efficacy trials.
Scrip - February 4, 2026
The FDA’s complete response letter for Aquestive Therapeutics’ allergy drug Anaphylm was limited to human factors validation and a single supportive pharmacokinetics study, defining a narrower path toward resubmission without additional efficacy trials.
Scrip - February 4, 2026
Novartis Plots Plan To Push Through Largest Patent Expiry In Its History
Sales set to rise at low single digits this year but profits will be down slightly as generics take a grip on big earners like Entresto.
Scrip - February 4, 2026
Sales set to rise at low single digits this year but profits will be down slightly as generics take a grip on big earners like Entresto.
Scrip - February 4, 2026
Super Bowl LX Ads: E.l.f. Kicks Off Telenovela; Dove Revisits Body Positivity; More
For Super Bowl LX on Feb. 8, e.l.f. Cosmetics will air a telenovela-inspired campaign with Academy Award-nominated actress Melissa McCarthy, as Dove features 30-second spot ‘The Game is Ours,’ to inspire body confidence in young girls. Separately, Manscaped launches first Super Bowl ad.
HBW Insight - February 4, 2026
For Super Bowl LX on Feb. 8, e.l.f. Cosmetics will air a telenovela-inspired campaign with Academy Award-nominated actress Melissa McCarthy, as Dove features 30-second spot ‘The Game is Ours,’ to inspire body confidence in young girls. Separately, Manscaped launches first Super Bowl ad.
HBW Insight - February 4, 2026
SK bioscience To Advance Gates MRI’s Novel RSV Antibody Contender
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Scrip - February 4, 2026
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Scrip - February 4, 2026
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market
Investors appeared not to be bothered by Amgen’s Q4 product updates, including the US FDA’s request to pull rare disease drug Tavneos from the market and discontinuation of Phase III bemarituzumab.
Scrip - February 4, 2026
Investors appeared not to be bothered by Amgen’s Q4 product updates, including the US FDA’s request to pull rare disease drug Tavneos from the market and discontinuation of Phase III bemarituzumab.
Scrip - February 4, 2026
Hawaii’s Age Restriction On Supplement Sales Also Would Require Behind-The-Counter Storage
Hawaii proposes age-restricted sales but, unlike similar bills also filed in Alaska, Massachusetts, Michigan and Washington legislatures, would require behind-the-counter storage to limit consumer access in stores.
HBW Insight - February 4, 2026
Hawaii proposes age-restricted sales but, unlike similar bills also filed in Alaska, Massachusetts, Michigan and Washington legislatures, would require behind-the-counter storage to limit consumer access in stores.
HBW Insight - February 4, 2026
Incyte’s Transition From A Jakafi Company To A More Diversified Pharma
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Scrip - February 4, 2026
CEO Bill Meury and president-R&D Pablo Cagnoni outlined the path to reduce Incyte’s reliance on the blockbuster Jakafi as it heads towards loss of exclusivity in 2028/2029.
Scrip - February 4, 2026
Novo Takes Gloomy Approach To Cut Weight Of Expectations
New CEO Mike Doustdar believes Novo Nordisk can win in the lower-price, higher-volume consumer market for obesity drugs – but is nonetheless preparing investors for a hit to sales and profits in 2026.
Scrip - February 4, 2026
New CEO Mike Doustdar believes Novo Nordisk can win in the lower-price, higher-volume consumer market for obesity drugs – but is nonetheless preparing investors for a hit to sales and profits in 2026.
Scrip - February 4, 2026
Novartis Gets Two New Blockbusters In Scemblix And Leqvio
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Scrip - February 4, 2026
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Scrip - February 4, 2026
GSK Bets On New Launches And R&D Acceleration As Sales Headwinds Remain
CEO Luke Miels backs GSK’s 2031 sales target of £40bn despite incoming headwinds in vaccines and HIV.
Scrip - February 4, 2026
CEO Luke Miels backs GSK’s 2031 sales target of £40bn despite incoming headwinds in vaccines and HIV.
Scrip - February 4, 2026
Novo Warns Of Steep Sales Decline In 2026, Blames US Price Cuts
The Danish firm’s share price plummeted as it revealed its most favored nation pricing deal would cut deep into sales and profits in 2026, although offset somewhat by strong launch of the Wegovy pill.
Scrip - February 4, 2026
The Danish firm’s share price plummeted as it revealed its most favored nation pricing deal would cut deep into sales and profits in 2026, although offset somewhat by strong launch of the Wegovy pill.
Scrip - February 4, 2026
FDA CRL for Aquestive’s Anaphylm Comes With Clearer Path Forward
The FDA’s complete response letter for Aquestive Therapeutics’ allergy drug Anaphylm was limited to human factors validation and a single supportive pharmacokinetics study, defining a narrower path toward resubmission without additional efficacy trials.
Scrip - February 4, 2026
The FDA’s complete response letter for Aquestive Therapeutics’ allergy drug Anaphylm was limited to human factors validation and a single supportive pharmacokinetics study, defining a narrower path toward resubmission without additional efficacy trials.
Scrip - February 4, 2026
Novartis Plots Plan To Push Through Largest Patent Expiry In Its History
Sales set to rise at low single digits this year but profits will be down slightly as generics take a grip on big earners like Entresto.
Scrip - February 4, 2026
Sales set to rise at low single digits this year but profits will be down slightly as generics take a grip on big earners like Entresto.
Scrip - February 4, 2026
SK bioscience To Advance Gates MRI’s Novel RSV Antibody Contender
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Scrip - February 4, 2026
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Scrip - February 4, 2026
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market
Investors appeared not to be bothered by Amgen’s Q4 product updates, including the US FDA’s request to pull rare disease drug Tavneos from the market and discontinuation of Phase III bemarituzumab.
Scrip - February 4, 2026
Investors appeared not to be bothered by Amgen’s Q4 product updates, including the US FDA’s request to pull rare disease drug Tavneos from the market and discontinuation of Phase III bemarituzumab.
Scrip - February 4, 2026
US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Lower US Tariffs Open Export Window For Indian Devices As Manufacturing Looks Away From China
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
More Accuracy Issues For Magellan Diagnostics Blood Lead Tests
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
Stryker Taps ASCs With Mako RPS As Mako 4 Drives Record Robot Installations
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Medtronic To Acquire Cathworks For $585M, Expanding Its Cardiology Portfolio
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
Clarity For Certain Botanicals With EU Novel Food Updates
The latest round of updates to the European Commission's Novel Food Catalogue determine whether authorization is required for supplements containing certain botanical extracts.
HBW Insight - February 4, 2026
The latest round of updates to the European Commission's Novel Food Catalogue determine whether authorization is required for supplements containing certain botanical extracts.
HBW Insight - February 4, 2026
Super Bowl LX Ads: E.l.f. Kicks Off Telenovela; Dove Revisits Body Positivity; More
For Super Bowl LX on Feb. 8, e.l.f. Cosmetics will air a telenovela-inspired campaign with Academy Award-nominated actress Melissa McCarthy, as Dove features 30-second spot ‘The Game is Ours,’ to inspire body confidence in young girls. Separately, Manscaped launches first Super Bowl ad.
HBW Insight - February 4, 2026
For Super Bowl LX on Feb. 8, e.l.f. Cosmetics will air a telenovela-inspired campaign with Academy Award-nominated actress Melissa McCarthy, as Dove features 30-second spot ‘The Game is Ours,’ to inspire body confidence in young girls. Separately, Manscaped launches first Super Bowl ad.
HBW Insight - February 4, 2026
Hawaii’s Age Restriction On Supplement Sales Also Would Require Behind-The-Counter Storage
Hawaii proposes age-restricted sales but, unlike similar bills also filed in Alaska, Massachusetts, Michigan and Washington legislatures, would require behind-the-counter storage to limit consumer access in stores.
HBW Insight - February 4, 2026
Hawaii proposes age-restricted sales but, unlike similar bills also filed in Alaska, Massachusetts, Michigan and Washington legislatures, would require behind-the-counter storage to limit consumer access in stores.
HBW Insight - February 4, 2026
Bausch And Lannett To Pay Up Nearly $18m In A US Price-Fixing Settlement
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
Sun On ‘Disciplined’ M&A Approach, Day-One Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
‘These Decisions Created A Lot Of Uncertainty’ – Why The Supreme Court’s Skinny-Label Ruling Matters
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
Santhera’s DMD Research Is A Labor Of Love
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
Medtech Companies Seek More Device Input Into EU’s Cardiovascular Disease Plan
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Financing Quarterly Statistics, Q4 2025
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026